Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
about
The neoepitope landscape in pediatric cancers.PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.Clinical implications of neoepitope landscapes for adult and pediatric cancersPan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes.Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances.Resources for Interpreting Variants in Precision Genomic Oncology Applications.Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.Aspirin in the era of immunotherapy.Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.Cholangiocarcinoma - evolving concepts and therapeutic strategies.Colorectal cancer in 2017: Practice-changing updates in the adjuvant and metastatic setting.Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients.Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil.Unveiling kaposi sarcoma viral antigens.Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy.Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy.Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy.Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Trial watch: Immune checkpoint blockers for cancer therapy.Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution.Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance.NF-kappaB: Two Sides of the Same Coin.Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.Immune checkpoint inhibitors in advanced non-small cell lung cancer.Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer.Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy.Identification of essential genes for cancer immunotherapy.Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.Towards personalized, tumour-specific, therapeutic vaccines for cancer.Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?
P2860
Q38601828-CF8921AD-BFD8-4303-BDA9-1A3C72F87DFDQ38642853-5B97794E-3BDB-4F1F-A0D2-41C4291593B8Q41571242-6DC65D30-59E2-48C5-A5AD-B65905352813Q42261796-399EA49E-16A6-45C3-BD91-8A7C56702483Q42353279-A08CE10A-8773-4575-9D1F-568DB8806896Q42363061-80F5BFD3-148B-444B-82D7-D5BAC873AF6AQ43578455-D8F49D06-008A-4EAF-BE6D-7596FCFA565EQ43990306-51B01C7E-DD78-4FAE-98FC-7254074D2678Q45072406-8D1ADD56-5A08-48B5-8C9B-F6C504681B09Q46083971-E33256B9-D100-4FE8-93AE-6DC5758B8637Q46087686-C474C330-C34D-4E5F-89EB-DA045D560146Q46115065-DD916766-3390-4A3B-9BFC-DB816F228534Q46721978-C47EC797-E708-481E-ABFA-48EB2096B998Q47098333-9AD39FBC-0D47-4C69-BE51-405993D8B928Q47120629-691BC99E-2432-46B2-BBE2-C91D4981C455Q47133741-D9A3C178-5615-40B6-A041-30661AD4765FQ47141058-C148E228-E59E-4796-BAB4-8FF741418A60Q47147071-E05ADE34-5748-44D1-B896-560F3E7465A1Q47149509-17DB1C9E-C40B-4F2B-A7EE-F3DB9E4DD1F0Q47236265-65CCD563-28D2-49C5-ACF7-293192F0FA2BQ47292249-C547D8A4-306A-46B9-93E0-756E055A5FFEQ47320909-E194B175-B423-4D0C-B369-623BE1A5A58CQ47321577-67B41064-AD06-4A5C-A9D1-9DE00A1BB4ABQ47325431-C1DD5F34-99C4-43FA-A430-3CBAD8DAFBC1Q47393365-01E93071-0806-4D66-8FFF-9F013C9E6893Q47433391-83A18648-9405-4818-AB79-3F6C8DFD305DQ47551609-8022E1BD-62F0-450D-9B8C-D3B43F6DCC6DQ47556651-57C0CB49-C31B-4BA3-B034-2F88D1CBEEDFQ47557087-C96D0AD7-5542-4DD9-BA38-478B96BBC83BQ47563451-8180DEA0-4EEA-4D3C-92B4-3C9E4B2F0B66Q47652834-7D4D9865-CF8E-40E0-9764-2AC046FA0131Q47701382-323064D3-796E-4B38-A7E1-891C72623C26Q47701712-08B47BB4-C3FF-4CDF-8471-62ED6AF41ECBQ47713578-D0F7917E-0BF0-46F9-82DC-10699DF9FF3DQ47718879-1B6E6C51-1DD2-4642-B2C8-7FEA3169BBC7Q47735303-1C2931E0-3227-4C51-8C29-1B1D166CB355Q47736099-189FBB59-1DA1-40A1-9FF8-3989EC4E4E6BQ47772214-A2D67EBB-37C5-4BEA-A81F-382F79FE53BCQ47789519-76EC93A2-2F74-4D10-80CA-542B2E4F8E3DQ47821832-818AA328-5AEC-405D-A4A0-66A3E6FE054F
P2860
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
@ast
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
@en
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
@nl
type
label
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
@ast
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
@en
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
@nl
prefLabel
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
@ast
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
@en
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
@nl
P2093
P2860
P50
P356
P1433
P1476
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
@en
P2093
Agnieszka A Rucki
Aleksandra D Eyring
Amanda N Fader
Andrew Joe
Brandon S Luber
Dan Laheru
David Spetzler
Deborah K Armstrong
Drew M Pardoll
P2860
P304
P356
10.1126/SCIENCE.AAN6733
P407
P50
P577
2017-06-08T00:00:00Z